The latest quarter from Ocugen tells two starkly different stories. Revenue blew past expectations by more than doubling consensus estimates, yet the bottom line missed by a penny and the company’s $115 million convertible note spooked the market. The stock now trades at €1.27, down roughly 19 percent over the past 30 days, with a relative strength index of 29.9 pointing to oversold territory.
Behind the numbers, Ocugen’s operational engine is running hot. First-quarter revenue came in at $1.53 million, a 205 percent beat on the $501,400 analysts had penciled in. But the net loss of $0.06 per share fell a cent short of the $0.05 loss forecast, and operating expenses swelled to $19.4 million. Research and development alone consumed $11.3 million of that total, reflecting the cost of pushing multiple gene therapy programs into late-stage trials.
The bigger market mover was the capital structure. Ocugen privately placed $115 million in convertible notes carrying a 6.75 percent coupon and maturing in 2034. Net proceeds are expected to reach roughly $99.5 million, of which $32.7 million will go to fully retire an existing loan carrying double-digit interest. Combined with the $32.2 million in cash and restricted cash Ocugen held at the end of March, management now projects the cash runway will extend into 2028.
On the operational front, the pipeline is gathering pace. Chief executive Dr. Shankar Musunuri confirmed that enrollment has closed for two late-stage programmes. The phase 2/3 study of OCU410ST in Stargardt disease — a rare inherited retinal condition with no approved therapy in the US or Europe — is fully recruited. Meanwhile, Ocugen reported positive topline data for OCU410 in geographic atrophy secondary to dry age-related macular degeneration. A year of follow-up showed that the middle dose group slowed the growth of macular lesions by a statistically significant 31 percent compared to the control.
Should investors sell immediately? Or is it worth buying Ocugen?
Two other candidates are also moving into regulatory spotlight. For OCU410, a pivotal phase 3 study is scheduled to kick off in the third quarter of 2026. Separately, Ocugen plans to begin the regulatory submission process for OCU400, aimed at retinitis pigmentosa, in late summer of the same year. The company’s stated goal is to file three marketing applications by 2028, with complete data for OCU410ST expected to be submitted to regulators by mid-2027.
Wall Street analysts have begun adjusting their outlooks. Oppenheimer initiated coverage with a buy rating this week, joining Canaccord Genuity, which started with a buy and a $12.00 price target. HC Wainwright raised its target to $10.00. All three cite the improved capital position and the advancing pipeline as reasons for optimism.
The stock’s recent performance tells a more cautious story. In US pre-market trading, shares fell more than 20 percent on the convertible announcement. Over in Germany, the stock closed at €1.25 on Monday before edging back to €1.27. The RSI reading of 29.9 suggests short-term oversold conditions, but the real test will come in the third quarter.
That period is shaping up to be the defining moment of the year. Ocugen must deliver the planned phase 3 start for OCU410 and push forward OCU400’s regulatory submission. If both milestones hit on schedule, the pipeline’s momentum could overpower the dilution and interest headwinds baked into the convertible note. Any slippage, however, will bring the debate over cash burn and financing structure roaring back to centre stage.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from May 12 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 12.
Ocugen: Buy or sell? Read more here...
